Several recent large trials just released long term follow-up results on overall survival. We look at what how treatment principles may change based on these mature data.
ECHELON-1 - Hodgkin's (A+AVD vs. ABVD)
POLO - Pancreatic (olaparib maintenance vs. placebo)
Keynote 355 - mTNBC (pembrolizumab + chemo vs. chemo)
APHinity - adjuvant HER+ breast (pertuzumab/trastuzumab vs. trastuzumab)
E1912 - CLL (ibrutinib/rituximab vs. FCR)